Altre lingue SinoMab BioScience Limited

Azioni

3681

HK0000544194

Mercato chiuso - Hong Kong S.E. Altri mercati azionari 10:08:07 09/05/2024			Variaz. 5gg	Var. 1 gen.
1,83 ^HKD	+0,55%		-3,68%	+8,93%

25/03	SinoMab BioScience Limited riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI
07/02	SinoMab BioScience Limited nomina Shanchun Wang come direttore esecutivo	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy	16/04
SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
SinoMab BioScience Limited Appoints Shanchun Wang as an Executive Director	07/02
SinoMab BioScience Raises HK$62.2 Million from Thirteen Share Subscriptions	15/01
SinoMab BioScience Issues 56.8 Million Shares to 15 Investors	15/12
SinoMab Doses First Batch of Subjects in Phase 1 Trial of Atopic Dermatitis Drug in China	28/11
SinoMab Bioscience Limited Announces First Cohort of the Health Subsidiaries Dosed in A Phase I Clinical Trial of SM17 in China	27/11
China Accepts Clinical Trial Application for SinoMab BioScience's Alzheimer's Treatment; Shares Rise 3%	16/11
Sinomab Bioscience Limited Announces IND Application for SM03 (Suciraslimab) for the Treatment of Alzheimer's Disease Accepted by NMPA CDE	15/11
China Accepts New Drug Application of SinoMab's Dermatitis Medication; Shares Rise 3%	12/09/23
SinoMab's IND Application of SM17 has once again Received Approval from NAMP	12/09/23
Sinomab Bioscience Limited announces Change of Non-Executive Directors	06/09/23
Chinese Regulator Accepts License Application for SinoMab's Arthritis Drug	05/09/23
China Accepts SinoMab's Biologics License Application for Arthritis Treatment	05/09/23
SinoMab BioScience Limited Announces National Medical Products Administration Accepts Biologics License Application for SM03 in the Treatment of Rheumatoid Arthritis	05/09/23
SinoMab Bioscience to Shrink Loss in H1	22/08/23
SinoMab BioScience Limited Reports Earnings Results for the Half Year Ended June 30, 2023	21/08/23
SinoMab Bioscience Obtains Clinical Trial Approval in China for Asthma Drug	15/08/23
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP	14/08/23
Sinomab Bioscience Limited Announces IND Approval for Sm17 by Nmpa	14/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue SinoMab BioScience Limited

Azioni

3681

HK0000544194

Altre lingue

Filtri